表紙
市場調查報告書

發熱物質實驗的全球市場:成長,趨勢,及預測(2019年∼2024年)

Pyrogen Testing Market - Growth, Trends, and Forecast (2019 - 2024)

出版商 Mordor Intelligence LLP 商品編碼 661045
出版日期 內容資訊 英文 116 Pages
商品交期: 2-3個工作天內
價格
Back to Top
發熱物質實驗的全球市場:成長,趨勢,及預測(2019年∼2024年) Pyrogen Testing Market - Growth, Trends, and Forecast (2019 - 2024)
出版日期: 2019年11月01日內容資訊: 英文 116 Pages
簡介

本報告提供全球發熱物質測試市場的相關調查,市場機會和趨勢,成長及阻礙因素,各產品、檢驗類型、終端用戶、地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 簡介

  • 調查成果
  • 調查的前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 成長要素
    • 製藥、生物科技產業的急速成長
    • 生命科學的研究開發費的增加
    • 經濟負擔的增加伴隨的慢性疾病的發生率的增加
  • 阻礙因素
    • 嚴格的政府法規
    • 無動物實驗法的採用相關壓力的增加
  • 波特的五力分析
    • 新加入廠商的威脅
    • 買主/消費者談判力
    • 供應商談判力
    • 替代產品的威脅
    • 產業內的競爭

第5章 市場區隔

  • 各產品
    • 套件、試劑
    • 服務
    • 設備
  • 各檢驗類型
    • LAL實驗
    • 兔子發熱物質實驗
    • 單球活性化實驗
    • 其他
  • 各終端用戶
    • 製藥、生物科技企業
    • 醫療設備企業
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • Lonza Group
    • Merck Kgaa
    • Ellab A/S
    • Genscript
    • BioMerieux
    • Thermo Fisher Scientific, Inc.
    • Wako Chemicals Usa, Inc.(Fujifilm 和光純藥株式會社)
    • WUXI Pharmatech (Cayman) Inc.
    • Associates of Cape Cod, Inc.
    • Charles River Laboratories, Inc.

第7章 市場機會及今後趨勢

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 60479

Market Overview

The market is primarily driven by increased demand for pyrogen testing products in the pharmaceutical and biotechnology industry and rising investments in research and development. The presence of well-developed healthcare infrastructure, well-defined rules, and regulations for pharmaceutical manufacturing process should help North America to dominate the market share in the forecast period.

Adding to that, the growing prevalence of chronic diseases is another primary factor driving the pyrogen testing market. The pyrogen testing has been found to be highly effective in case of airborne diseases such as chronic obstructive lung diseases and childhood asthma, where it quantitively assess the human-relevant airborne pyrogens. These tests are further highly useful in detecting contamination related to an inflammatory response in cases of chronic kidney disorders. The chronic diseases prevalence is high in developed countries and is growing at a high rate in emerging markets. Thus, the demand for pyrogen testing with increasing awareness is resulting in high growth over the forecast period.

Other factors driving this market are high investments in research and development in the life science industry, the rise in the number of pharmaceutical and biotechnological companies and rise in the launch of biologic products and surge in new innovative drugs.

Scope of the Report

Pyrogen testing refers to the process of determining microbes or the presence of their metabolites in drugs and intravenous solutions during their manufacture.

Key Market Trends

Monocyte Activation Test is Expected to Witness Highest Growth Rate

The measurement of pyrogens is an essential safety measure for pharmaceutical products with parenteral administration and for medical devices. The Monocyte Activation Test is used to detect or quantify substances that activate human monocytes or monocytic cells to release endogenous mediators which have a role in the human fever response. alternatives to Rabbit Pyrogen Test were developed taking into account the fever induction mechanism of pyrogen-induced cytokines. The monocyte activation test (MAT), for example, is based on the detection of IL-6 or IL-1b induced in human blood monocytes or monocytic cell lines stimulated in vitro by pyrogens.

It has been suggested by the Brazilian Journal of Pharmaceutical Science that the Monocyte Activation Test is getting more attention in the pharmaceutical industry which in turn is contributing to the rapid growth of the same.

The United States to Dominate the Market in the Forecast Period

The United States is expected to dominate the market share with well-established healthcare infrastructure, better regulatory framework, and government support and presence of many large biotechnological and biopharmaceutical firms, such as Merck, Lonza Group, among others. These companies have a high focus on new drug and biologics development with continuous support from the government in the form of funding from several government bodies and investors, which fuel the growth of this market. The Asia Pacific is expected to exhibit the highest growth rate. The healthy CAGR is expected due to rising healthcare expenditure in countries, such as India, China, and Japan. This is accompanied by lesser stringency in government regulations for drug development.

Competitive Landscape

The market for the pyrogen testing is moderately competitive and is dominated by a few major players such as Merck KGaA, Lonza Group, BioMerieux, and GenScript. With the rising innovations in the in-vitro testing, there are novel players that are also entering the market and throwing competition to gain the market share.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

TABLE OF CONTENTs

1. INTRODUCTION

  • 1.1. Study Deliverables
  • 1.2. Study Assumptions
  • 1.3. Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1. Market Overview
  • 4.2. Market Drivers
    • 4.2.1. Rapid Growth in Pharmaceutical and Biotechnology Industries
    • 4.2.2. Growing R&D Expenditure in life Science
    • 4.2.3. Increasing Incidence of Chronic Diseases Along With its Rising Economic Burden
  • 4.3. Market Restraints
    • 4.3.1. Stringent Government Regulations
    • 4.3.2. Rising Pressure in Regards to Adoption of Animal Free Testing Methods
  • 4.4. Porter's Five Force Analysis
    • 4.4.1. Threat of New Entrants
    • 4.4.2. Bargaining Power of Buyers/Consumers
    • 4.4.3. Bargaining Power of Suppliers
    • 4.4.4. Threat of Substitute Products
    • 4.4.5. Intensity of Competitive Rivalry

5. MARKET SEGMENTATION

  • 5.1. By Product
    • 5.1.1. Kits and Reagents
    • 5.1.2. Services
    • 5.1.3. Instruments
  • 5.2. By Test Type
    • 5.2.1. LAL Tests
      • 5.2.1.1. Chromogenic Tests
      • 5.2.1.2. Turbidimetric Tests
      • 5.2.1.3. Gel Clot Tests
    • 5.2.2. Rabbit Pyrogen Test
    • 5.2.3. Monocyte Activation Test
    • 5.2.4. Others
  • 5.3. By End User
    • 5.3.1. Pharmaceutical and Biotechnology Companies
    • 5.3.2. Medical Device Companies
    • 5.3.3. Others
  • 5.4. Geography
    • 5.4.1. North America
      • 5.4.1.1. US
      • 5.4.1.2. Canada
      • 5.4.1.3. Mexico
    • 5.4.2. Europe
      • 5.4.2.1. Germany
      • 5.4.2.2. UK
      • 5.4.2.3. France
      • 5.4.2.4. Italy
      • 5.4.2.5. Spain
      • 5.4.2.6. Rest of Europe
    • 5.4.3. Asia Pacific
      • 5.4.3.1. China
      • 5.4.3.2. Japan
      • 5.4.3.3. India
      • 5.4.3.4. Australia
      • 5.4.3.5. South Korea
      • 5.4.3.6. Rest of Asia-Pacific
    • 5.4.4. Middle East and Africa
      • 5.4.4.1. GCC
      • 5.4.4.2. South Africa
      • 5.4.4.3. Rest of Middle East and Africa
    • 5.4.5. South America
      • 5.4.5.1. Brazil
      • 5.4.5.2. Argentina
      • 5.4.5.3. Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1. Company Profiles
    • 6.1.1. Lonza Group
    • 6.1.2. Merck Kgaa
    • 6.1.3. Ellab A/S
    • 6.1.4. Genscript
    • 6.1.5. BioMerieux
    • 6.1.6. Thermo Fisher Scientific, Inc.
    • 6.1.7. Wako Chemicals Usa, Inc.
    • 6.1.8. WUXI Pharmatech (Cayman) Inc.
    • 6.1.9. Associates of Cape Cod, Inc.
    • 6.1.10. Charles River Laboratories, Inc.

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top